Literature DB >> 12437043

Typhoid fever in Kuala Lumpur and a comparative evaluation of two commercial diagnostic kits for the detection of antibodies to Salmonella typhi.

V Gopalakrishnan1, W Y Sekhar, E H Soo, R A Vinsent, S Devi.   

Abstract

The aim of this study was to compare two commercial kits, theTyphidot and the PanBio ELISA with the present Widal test. Demographic data for all serodiagnosed cases for the years 1991-1998 were collected. From this data, 144 were selected as samples for comparative evaluation of the commercial kits. Fifty sera were culture positive for Salmonella typhi, 50 were culture negative but clinically diagnosed as typhoid fever and Widal positive and 44 were serodiagnosed as enteric of which 21 were culture positive for other Salmonella species, 20 were serodiagnosed for other febrile illnesses and three sera culture positive for other species of enterobacteriaceae. The specificity, sensitivity and efficiency of the tests were calculated with the positive culture for S. typhi as the gold standard. Sensitivity, specificity and efficiency of test for Typhidot and Typhidot M kits were 98%, 76.6% and 84.0% and PanBio ELISA were 78%, 80% and 79.9%. The two commercial kits evaluated were found to be less time consuming and easier to perform than Widal. The Typhidot M seems to be a practical alternative in the field and in small hospitals with lesser facilities.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12437043

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  9 in total

Review 1.  Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections.

Authors:  John A Crump; Maria Sjölund-Karlsson; Melita A Gordon; Christopher M Parry
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

2.  Evaluation of rapid diagnostic tests for typhoid fever.

Authors:  Sonja J Olsen; Jim Pruckler; William Bibb; Thi My Thanh Nguyen; My Trinh Tran; Thi Minh Nguyen; Sumathi Sivapalasingam; Amita Gupta; Thu Phuong Phan; Tran Chinh Nguyen; Vinh Chau Nguyen; Dac Cam Phung; Eric D Mintz
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

Review 3.  Rapid diagnostic tests for typhoid and paratyphoid (enteric) fever.

Authors:  Lalith Wijedoru; Sue Mallett; Christopher M Parry
Journal:  Cochrane Database Syst Rev       Date:  2017-05-26

Review 4.  A systematic review and meta-analysis of the performance of two point of care typhoid fever tests, Tubex TF and Typhidot, in endemic countries.

Authors:  Kamala Thriemer; Benedikt Ley; Joris Menten; Jan Jacobs; Jef van den Ende
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

5.  A comparative study of Widal test with blood culture in the diagnosis of typhoid fever in febrile patients.

Authors:  Gizachew Andualem; Tamrat Abebe; Nigatu Kebede; Solomon Gebre-Selassie; Adane Mihret; Haile Alemayehu
Journal:  BMC Res Notes       Date:  2014-09-17

Review 6.  Single Domain Antibodies as New Biomarker Detectors.

Authors:  Chiuan Herng Leow; Katja Fischer; Chiuan Yee Leow; Qin Cheng; Candy Chuah; James McCarthy
Journal:  Diagnostics (Basel)       Date:  2017-10-17

7.  A Meta-Analysis of Typhoid Diagnostic Accuracy Studies: A Recommendation to Adopt a Standardized Composite Reference.

Authors:  Helen L Storey; Ying Huang; Chris Crudder; Allison Golden; Tala de los Santos; Kenneth Hawkins
Journal:  PLoS One       Date:  2015-11-13       Impact factor: 3.240

Review 8.  Typhoid Fever Diagnosis in Endemic Countries: A Clog in the Wheel of Progress?

Authors:  Olumide Ajibola; Mari B Mshelia; Bashar H Gulumbe; Anthonius A Eze
Journal:  Medicina (Kaunas)       Date:  2018-04-25       Impact factor: 2.430

9.  Typhoid fever among febrile Nigerian patients: Prevalence, diagnostic performance of the Widal test and antibiotic multi-drug resistance.

Authors:  Martin E Ohanu; Michael O Iroezindu; Uzoamaka Maduakor; Obinna D Onodugo; Harish C Gugnani
Journal:  Malawi Med J       Date:  2019-09       Impact factor: 0.875

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.